Genetic Testing for Breast, Ovarian Cancer Risk Safely Done at Home, Trial Shows

Genetic Testing for Breast, Ovarian Cancer Risk Safely Done at Home, Trial Shows
Genetic tests to assess the risk of breast and ovarian cancer can be performed remotely in the safety of the patients’ homes, according to data from an early Phase 1 trial. The trial findings also showed that genetic counseling sessions performed before and after testing can be skipped entirely without causing additional distress to patients. Data from the study was included in an oral presentation titled “Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk.” It was presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held online May 29-31. Certain types of hereditary breast and ovarian cancers may be avoided altogether if women with an increased genetic predisposition are promptly identified and treated before developing the disease. However, genetic tests used to identify these patients are not easily accessible to everyone. As a result, many women who have a high genetic predisposition to develop these types of cancers end up not being tested. MAGENTA (Making GENetic Testing Accessible) is an early Phase 1 trial (NCT02993068) that aims to improve the accessibility of genetic tests for women at risk of hereditary cancers, through the use of a remote genetic testing service. The study seeks to determine if remote genetic
Subscribe or to access all post and page content.